Hospital
Ohi West, INC
Ohi West, INC was paid $10.31M by Medicaid between Jan 2018 and Dec 2024, across 230 billing codes. Its largest line is 99284, emergency room visit (serious) — 21% of everything it billed.
33Billing provider infoOHI WEST, INC
ST PETERSBURG, FL 33701
ST PETERSBURG, FL 33701
33aNPI1912975228assigned 03/11/2006
33bProvider typeRehabilitation Hospital Unit
28Total paid$10.31M
24GClaims658,388
24DCodes billed230
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rehabilitation Hospital Unit providers in Florida
Rank by total paid#7 of 11
Median peer was paid$15.92M
This provider vs. median0.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 76,681 | $390K | |
| 2019 | 148,669 | $1.90M | |
| 2020 | 139,824 | $1.48M | |
| 2021 | 118,130 | $1.78M | |
| 2022 | 97,481 | $2.20M | |
| 2023 | 56,512 | $1.85M | |
| 2024incomplete | 21,091 | $712K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 29,474 | 23,829 | $2.21M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 25,038 | 21,598 | $1.78M |
| 36415 | Collection of venous blood by venipuncture | 11% | 60,528 | 39,863 | $1.10M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.3% | 14,024 | 11,251 | $753K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.0% | 9,642 | 7,590 | $410K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 3,687 | 3,054 | $371K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.0% | 1,811 | 1,533 | $208K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 3,234 | 2,770 | $202K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.9% | 724 | 640 | $192K |
| 59025 | Fetal non-stress test | 1.8% | 2,409 | 1,861 | $187K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 6,658 | 5,155 | $165K |
| 80053 | Comprehensive metabolic panel | 1.5% | 37,040 | 27,070 | $157K |
218 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 2,870 | $146K |
| 86901 | 1.4% | 3,589 | $141K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.3% | 3,434 | $132K |
| 84484 | <1% | 10,505 | $95K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,776 | $91K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,298 | $89K |
| 83690 | <1% | 7,210 | $85K | |
| 87205 | <1% | 8,553 | $84K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,028 | $81K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,355 | $79K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 859 | $69K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,305 | $61K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 3,439 | $58K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 149 | $56K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,387 | $56K |
| 97161 | <1% | 911 | $54K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,335 | $53K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,765 | $52K |
| 81025 | <1% | 10,711 | $48K | |
| 81001 | <1% | 24,127 | $42K | |
| 82962 | <1% | 5,096 | $33K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,685 | $31K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 652 | $31K |
| G0378 | Hospital observation service, per hour | <1% | 3,476 | $30K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,810 | $29K |
| 87400 | <1% | 1,730 | $28K | |
| 87070 | <1% | 617 | $26K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,446 | $25K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 998 | $23K |
| 76801 | <1% | 2,798 | $23K | |
| 83605 | <1% | 1,680 | $23K | |
| 74174 | <1% | 152 | $22K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,007 | $21K |
| 73610 | <1% | 989 | $20K | |
| 80047 | <1% | 3,919 | $20K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,533 | $20K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,091 | $20K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,569 | $20K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,606 | $19K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 16,653 | $18K |
| 87186 | <1% | 2,142 | $18K | |
| 86900 | <1% | 3,603 | $18K | |
| 73130 | <1% | 1,040 | $16K | |
| 73562 | <1% | 1,530 | $16K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 401 | $16K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,142 | $16K |
| 84702 | <1% | 5,396 | $14K | |
| 83735 | <1% | 4,585 | $14K | |
| 73030 | <1% | 1,037 | $13K | |
| 73630 | <1% | 1,135 | $13K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 42,191 | $13K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 3,366 | $12K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,646 | $11K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,036 | $10K |
| 87631 | <1% | 1,565 | $10K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,413 | $10K |
| 87430 | <1% | 950 | $10K | |
| 93971 | <1% | 888 | $9K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,150 | $9K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,685 | $9K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 5,514 | $9K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 492 | $9K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,766 | $8K |
| 97597 | <1% | 139 | $8K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,498 | $8K |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 14,661 | $8K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,370 | $8K |
| 10060 | <1% | 173 | $8K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 14 | $8K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 283 | $7K |
| 97162 | <1% | 146 | $7K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 538 | $7K |
| 99218 | <1% | 1,855 | $7K | |
| 83615 | <1% | 1,377 | $6K | |
| 70491 | <1% | 15 | $6K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,594 | $6K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,680 | $5K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,976 | $5K |
| 82746 | <1% | 1,315 | $5K | |
| 70486 | <1% | 594 | $5K | |
| 82550 | <1% | 2,753 | $5K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 28 | $5K |
| 93970 | <1% | 402 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,291 | $5K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $5K |
| 85027 | <1% | 8,218 | $4K | |
| 85610 | <1% | 7,184 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,064 | $4K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 110 | $4K |
| 83880 | <1% | 2,145 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,667 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,463 | $4K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 975 | $3K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,680 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,048 | $3K |
| 73110 | <1% | 337 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,747 | $3K |
| 76818 | <1% | 62 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,205 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,498 | $2K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 354 | $2K |
| 82607 | <1% | 2,988 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 506 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,882 | $2K |
| 80061 | Lipid panel | <1% | 5,071 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,253 | $2K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 100 | $2K |
| 85014 | <1% | 3,990 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,453 | $2K |
| 86592 | <1% | 838 | $2K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 309 | $2K |
| 72100 | <1% | 216 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,609 | $1K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 107 | $1K |
| 73502 | <1% | 149 | $1K | |
| 87210 | <1% | 797 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,758 | $1K |
| 80076 | <1% | 377 | $1K | |
| 01999 | <1% | 292 | $1K | |
| 76641 | <1% | 23 | $935.37 | |
| 74018 | <1% | 57 | $907.97 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 956 | $899.04 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 34 | $887.21 |
| 85730 | <1% | 2,204 | $880.17 | |
| 87077 | <1% | 1,812 | $871.45 | |
| 90715 | <1% | 993 | $834.65 | |
| 97116 | <1% | 146 | $827.53 | |
| 80164 | <1% | 414 | $812.82 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,048 | $768.17 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 58 | $740.56 |
| 82140 | <1% | 273 | $740.13 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,735 | $715.24 |
| 84439 | <1% | 2,061 | $697.23 | |
| 80074 | <1% | 62 | $681.91 | |
| 85379 | <1% | 2,030 | $676.51 | |
| 96376 | <1% | 1,162 | $647.42 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 51 | $561.88 |
| 82570 | <1% | 1,901 | $541.63 | |
| 86850 | <1% | 2,246 | $522.19 | |
| 87806 | <1% | 14 | $480.15 | |
| 99499 | <1% | 16 | $452.39 | |
| 85652 | <1% | 1,395 | $418.13 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,053 | $404.18 |
| 87081 | <1% | 439 | $396.44 | |
| 76642 | <1% | 16 | $374.76 | |
| 72131 | <1% | 54 | $359.96 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 124 | $333.70 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 507 | $324.48 |
| 72110 | <1% | 28 | $324.18 | |
| 12002 | <1% | 13 | $307.64 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 693 | $266.07 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 243 | $258.64 |
| 86141 | <1% | 1,313 | $255.02 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,428 | $254.11 |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 14 | $229.78 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 459 | $216.90 |
| 94760 | <1% | 1,230 | $207.02 | |
| 82150 | <1% | 281 | $193.74 | |
| 82330 | <1% | 304 | $180.80 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 220 | $169.95 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 455 | $168.41 |
| 73590 | <1% | 32 | $153.33 | |
| 84156 | <1% | 1,370 | $139.05 | |
| 84703 | <1% | 398 | $130.04 | |
| 82728 | <1% | 634 | $116.54 | |
| 81003 | <1% | 2,067 | $115.11 | |
| 84550 | <1% | 1,475 | $113.87 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 829 | $101.36 |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 317 | $100.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 165 | $91.45 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 70 | $56.14 |
| 80177 | <1% | 143 | $55.94 | |
| 76857 | <1% | 17 | $44.30 | |
| 86706 | <1% | 48 | $41.60 | |
| 84100 | <1% | 286 | $34.78 | |
| 83540 | <1% | 825 | $33.05 | |
| 88342 | <1% | 181 | $31.30 | |
| 82248 | <1% | 157 | $30.88 | |
| 82043 | <1% | 141 | $26.84 | |
| 82803 | <1% | 14 | $25.19 | |
| 84132 | <1% | 252 | $25.19 | |
| 84295 | <1% | 244 | $25.19 | |
| 82947 | <1% | 265 | $25.19 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 146 | $21.66 |
| 87340 | <1% | 115 | $20.23 | |
| 83550 | <1% | 125 | $19.30 | |
| 84145 | <1% | 77 | $16.28 | |
| 94644 | <1% | 26 | $13.46 | |
| 84480 | <1% | 101 | $9.07 | |
| 84630 | <1% | 21 | $7.84 | |
| 72040 | <1% | 19 | $7.47 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 43 | $3.36 |
| 82553 | <1% | 59 | $0.86 | |
| 85018 | <1% | 94 | $0.43 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 459 | $0.00 |
| 82435 | 0% | 225 | $0.00 | |
| 84134 | 0% | 23 | $0.00 | |
| 86803 | 0% | 29 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 19 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 186 | $0.00 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 0% | 37 | $0.00 |
| 87040 | 0% | 69 | $0.00 | |
| 87581 | 0% | 33 | $0.00 | |
| 87486 | 0% | 33 | $0.00 | |
| G0379 | Direct admission of patient for hospital observation care | 0% | 12 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 34 | $0.00 |
| 87147 | 0% | 17 | $0.00 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 25 | $0.00 |
| 73080 | 0% | 29 | $0.00 | |
| 84520 | 0% | 220 | $0.00 | |
| 82565 | 0% | 241 | $0.00 | |
| 00840 | 0% | 27 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 15 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 20 | $0.00 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 33 | $0.00 |
| 00731 | 0% | 13 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 32 | $0.00 |
| Q0114 | Fern test | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTUBEE, MICHAEL (AVP)
| Provider | Location | Paid |
|---|---|---|
| Physician Associates LLC | Orlando, FL | $4.69M |
| Ohi West, INC | St Petersburg, FL | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.